IP Library › Patent Application 15157920
Patent Application
App. No. 15/157,920

USE OF PLATELET RICH PLASMA COMPOSITION IN THE TREATMENT OF CARDIAC CONDUCTION ABNORMALITIES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/157,920
Abstract

Methods and kits for treating a cardiac arrhythmia using a platelet rich plasma (PRP) composition are provided. Any type of arrhythmia may be treated using the PRP composition. The PRP composition may comprise PRP developed using blood collected from a patient suffering the cardiac arrhythmia. The PRP composition may be buffered to a physiological pH and may include one or more anti-arrhythmic agents, anti-coagulants, or other drugs. The PRP composition may be delivered using a nebulizer, minimally invasively, or surgically.

Claims (29)

1 . A method for treating a issue injury, comprising:

identifying a tissue injury in a patient; and

delivering a platelet rich plasma (PRP) composition to the patient in an amount sufficient to treat the tissue injury, wherein the platelet rich plasma composition is in an inhalable form.

2 - 7 . (canceled)

8 . The method of claim 1 , wherein the platelet rich plasma composition is prepared from whole blood of the patient.

9 . The method of claim 1 , wherein the platelet rich plasma composition is buffered to a physiological pH, and wherein the physiological pH is between about 7.3 and about 7.5.

10 . The method of claim 1 , wherein the inhalable form is an inhalable powder.

11 . (canceled)

12 . The method of claim 1 , wherein the inhalable form is delivered with a nebulizer or inhaler.

13 . (canceled)

14 . A kit comprising:

a nebulizer or inhaler comprising platelet rich plasma in an inhalable form.

15 - 20 . (canceled)

21 . The method of claim 1 , wherein the injured tissue is selected from the group consisting of stomach, abdominal wall, bladder, and vascular tissue.

22 . The method of claim 1 , wherein the inhalable form is a dry powder.

23 . The method of claim 1 , wherein the inhalable form is a PRP composition delivered with a nebulizer or inhaler.

24 . A method of preparing platelet rich plasma (PRP) comprising

isolating platelets; and

drying the isolated platelets.

25 . The method of claim 24 , wherein the platelets are buffered to a physiological pH, and wherein the physiological pH is between about 7.3 and about 7.5.

26 . A method of preparing PRP in an inhalable form comprising:

collecting blood from a patient;

isolating platelets from the collected blood;

suspending the isolated platelets in plasma to form a PRP composition;

providing the isolated PRP composition in an inhaler or nebulizer.

27 . The method of claim 26 , wherein the platelets are isolated by centrifugation.

28 . The method of claim 26 , wherein the platelet rich plasma composition is buffered to a physiological pH, and wherein the physiological pH is between about 7.3 and about 7.5.

29 . The method of claim 26 , further comprising leukoreducing the PRP composition.

30 . The method of claim 26 , further comprising immunoadsorbing the PRP composition.